The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2

Cisplatin is one of the primary compounds used in the treatment of nasopharyngeal carcinoma (NPC), and fibroblast growth factor receptor 2 (FGFR2) has emerged to be a promising target for treatment in various tumors. Therefore, the present study aimed to explore whether the expression levels of FGFR...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Li, Su, Lizhong, Kang, Xixun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559331/
https://www.ncbi.nlm.nih.gov/pubmed/31115494
http://dx.doi.org/10.3892/ijmm.2019.4193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559331/
https://www.ncbi.nlm.nih.gov/pubmed/31115494
http://dx.doi.org/10.3892/ijmm.2019.4193

Ejemplares similares